{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 68. ASH 2025 Myeloma Special: MajesTEC-3 and the Bispecific Revolution with Dr. Luciano Costa","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/7f2b38c0\"></iframe>","width":"100%","height":180,"duration":2750,"description":" Join hosts Raj, Ashwin, and Eddie in this episode of Blood Cancer Talks as they welcome Dr. Luciano Costa, the first author of the NEJM manuscript on the MajesTEC-3 RCT, which was presented at ASH 2025. This episode dives deep into the trial's topline findings, capturing the nuances of the patient population, efficacy and safety data, and the future implications for treatment. The episode also examines the comparative efficacy of bispecific T-cell engagers versus CAR-T therapies, along with spirited discussion on the potential for fixed-duration treatment in myeloma care. \nEpisode Highlights \nMain Topics Covered \nMajesTEC-3 Trial: Teclistamab-Daratumumab vs. Standard of Care Trial design and patient population\nPrimary endpoint: Progression-free survival (PFS)\nMRD negativity rates and depth of response\nOverall survival and safety profile\nClinical implications for treatment selection\nTreatment Selection in Early Relapse Comparing MajesTEC-3 and CARTITUDE-4 patient populations\nFramework for choosing between bispecific antibodies vs. CAR T-cell therapy\nManaging anti-CD38 exposed patients\n\nLink to the NEJM paper: https://www.nejm.org/doi/abs/10.1056/NEJMoa2514663\n \n ","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}